Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 10 2022 - 4:01PM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with cancer and
autoimmune diseases, today reported the grant of 8,000 restricted
stock units of Atara’s common stock to one newly hired employee.
This award was approved by the Compensation Committee of Atara’s
Board of Directors and granted under the Atara Biotherapeutics,
Inc. 2018 Inducement Plan, with a grant date of October 3, 2022, as
an inducement material to the new employee entering into employment
with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent
vesting on the first quarterly vesting date after the first
anniversary of the vesting commencement date and the remainder
vesting in 12 approximately equal quarterly installments over the
following three years, subject to the employee being continuously
employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc. Atara Biotherapeutics,
Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging
its novel allogeneic EBV T-cell platform to develop transformative
therapies for patients with serious diseases including solid
tumors, hematologic cancers and autoimmune disease. With our lead
program in Phase 3 clinical development, Atara is the most advanced
allogeneic T-cell immunotherapy company and intends to rapidly
deliver off-the-shelf treatments to patients with high unmet
medical need. Our platform leverages the unique biology of EBV T
cells and has the capability to treat a wide range of
EBV-associated diseases, or other serious diseases through
incorporation of engineered CARs (chimeric antigen receptors) or
TCRs (T-cell receptors). Atara is applying this one platform, which
does not require TCR or HLA gene editing, to create a robust
pipeline including: tab-cel in Phase 3 development for Epstein-Barr
virus-driven post-transplant lymphoproliferative disease (EBV+
PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy
targeting EBV antigens as a potential treatment for multiple
sclerosis; and multiple next-generation chimeric antigen receptor
T-cell (CAR-T) immunotherapies for both solid tumors and
hematologic malignancies. Improving patients’ lives is our mission
and we will never stop working to bring transformative therapies to
those in need. Atara is headquartered in South San Francisco. For
additional information about the company, please visit atarabio.com
and follow us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221006005752/en/
INVESTOR & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com
Media Alex Chapman 805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2024 to Jun 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jun 2023 to Jun 2024